Antiplatelet Therapy for Secondary Stroke Prevention in Patients with Ischemic Stroke or Transient Ischemic Attack

Article information

Cardiovasc Prev Pharmacother. 2021;3(4):86-94

Publication date (electronic) : 2021 October 31

doi : https://doi.org/10.36011/cpp.2021.3.e10

Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Correspondence to Kyung-Yul Lee, MD, PhD Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonju-ro, Gangnam-gu, Seoul 06273, Korea. E-mail: kylee@yuhs.ac

Received 2021 October 10; Accepted 2021 October 31.

Abstract

The risk of stroke recurrence is highest in the acute phase after transient ischemic attack (TIA) or ischemic stroke. Therefore, patients with TIA or ischemic stroke should be treated with antiplatelet medication for stroke prevention. The short-term use of dual antiplatelet therapy between 21 and 90 days may be considered in those with acute minor stroke or TIA and high-risk of recurrence. However, the long-term use of dual antiplatelet therapy is not recommended due to the risk of bleeding. The current stroke guideline does not specify the administration of an antiplatelet for the secondary prevention of ischemic stroke. However, as clinical studies progress, antiplatelet therapy may become a personalized treatment in the future.

Keywords: Ischemic stroke; Platelet aggregation inhibitors; Secondary prevention; Stroke

INTRODUCTION

Stroke is a leading cause of mortality and permanent disability worldwide.1) Acute cerebral ischemia such as cerebral infarction and transient ischemic attack (TIA), is often followed by recurrent ischemic events, where recurrent stroke or TIA occurs in 12% of cases at 1 year and 16.8% at 5 years after minor stroke or TIA.2)3) The secondary prevention of recurrent stroke includes the control of risk factors, such as hypertension, diabetes mellitus, and dyslipidemia; lifestyle modification, such as smoking cessation, weight reduction, and regular physical activity; antiplatelet therapy for non-cardioembolic ischemic stroke; and anticoagulation therapy for cardioembolic ischemic stroke.4) This review will focus on the strategy of antiplatelet therapy administration for the secondary prevention of noncardioembolic ischemic stroke or TIA in various situations and time points.

ACUTE MINOR STROKE OF HIGH-RISK TIA

A high-risk of recurrent stroke after TIA or minor stroke exists in the early period, with most strokes occurring within the first 2 days5-8); therefore, more effective preventive treatment modalities are needed at this time. The secondary preventive effect of antiplatelet therapy after ischemic stroke has been well-established. In the past, secondary stroke prevention guidelines recommended the use of single antiplatelet (aspirin, clopidogrel) for initial treatment. Although, the combination of aspirin and clopidogrel is more effective than the use of aspirin alone in reducing the risk of ischemic events in patients with acute coronary syndrome,9) the addition of aspirin to clopidogrel is not recommended for secondary prevention after ischemic stroke or TIA due to the increased risk of bleeding. The MATCH trial randomized patients with a recent TIA or ischemic stroke to clopidogrel plus aspirin versus clopidogrel plus placebo groups. The antiplatelet combination did not reduce major vascular effects, but increased the risk of life threatening events or major bleeding.10) However, this study did not reflect the prevention of recurrent stroke in the early period after the initial event. The mean time from the qualifying event to randomization was 27 days, and subgroup analysis showed a favorable trend of dual antiplatelet agent in the group with early randomization (within 7 days).

The recent stroke secondary prevention guideline recommends that early initiation of short-term (21–90 days) dual antiplatelet therapy with aspirin and clopidogrel (or ticagrelor), ideally within 12–24 hours, and at least within 7 days after the onset of minor stroke (National Institutes of Health Stroke Scale [NIHSS] ≤ 3, NIHSS ≤ 5 for ticagrelor) or high-risk TIA (ABCD2 score ≥ 4, ABCD2 score ≥ 6 for ticagrelor). This guideline is based on three major randomized controlled trials11-13) and meta-analyses14-18) (Table 1). The use of dual antiplatelet therapy with aspirin and clopidogrel beyond 90 days after stroke is not recommended due to the increased risk of intracranial hemorrhage and major bleeding10) (Figure 1).

Table 1.

Clinical trials of dual antiplatelet therapy for secondary stroke prevention in acute minor stroke or transient ischemic attack

Figure 1.

Antiplatelet therapy for non-cardioembolic stroke and transient ischemic attack.

^*Dual antiplatelet is ideally initiated within 24 hours of symptom onset but can be given within 7 days of stroke onset; ^†Intracranial artery stenosis is defined as stenosis >50%; ^‡High-risk TIA is defined as an ABCD2 score ≥4; ^§The benefit of dual antiplatelet therapy was primarily observed during the first 21 days after symptom onset in major clinical trials; ^llDual antiplatelet means the combination of aspirin and clopidogrel (modified from the Figure of Stroke 2021;52:e364-46715)).

TIA = transient ischemic attack; NIHSS = National Institutes of Health Stroke Scale.

Single antiplatelet therapy is recommended for acute stroke patients who do not meet the dual antiplatelet clinical criteria (minor stroke or high-risk TIA, intracranial or extracranial arterial stenosis). Several antiplatelet agents, including aspirin (50–325 mg daily) and clopidogrel (75 mg daily), or the combination of aspirin 25 mg and extended-release dipyridamole 200 mg twice daily, are recommended for the secondary prevention of ischemic stroke.19-21)

INTRACRANIAL LARGE ARTERY ATHEROSCLEROSIS

Intracranial atherosclerosis (ICAS) is a common cause of stroke worldwide,22)23) but is more prevalent in Asian and Black ethnicities than in Caucasians. The annual stroke recurrence rate in patients with ICAS is approximately 4–19%, and it remains as high as 15% in the first year despite optimal medical treatment in several clinical trials comparing the preventive effect of endovascular and medical treatment.24-27)

Several randomized controlled trials have compared percutaneous transluminal angioplasty and stenting (PTAS) with medical therapy for stroke prevention in patients with recent stroke or TIA attributable to severe arterial stenosis. These trials showed a higher rate of cerebrovascular events or death in the PTAS group than in the medical therapy group25)26)28)29) (Table 2).

Table 2.

Clinical trials of intracranial stent for secondary stroke prevention

The stroke prevention guideline recommends the use of dual antiplatelet medication (addition of clopidogrel 75 mg per day to aspirin for up to 90 days) in patients with recent (within 30 days) stroke or TIA attributable to severe (70–99%) ICAS. Further, the guideline recommends the addition of ticagrelor 90 mg to aspirin twice a day for up to 30 days in patients with recent (within 24 hours) minor stroke or high-risk TIA and concomitant ipsilateral >30% stenosis of a major intracranial artery. Although the guideline does not recommend long-term dual antiplatelet therapy beyond 3 months, a previous long-term cohort study reported a higher risk of recurrent stroke in patients with severe (50–99%) ICAS than in those without.30) Additional studies are needed to determine the effect of long-term dual antiplatelet therapy and to establish the specific high-risk subgroup of recurrent stroke in patients with severe symptomatic ICAS.

The medical arm of the SAMMPRIS trial was treated with solely 325 mg aspirin once daily after the first 90 days of dual antiplatelet therapy for the secondary prevention of stroke in severe ICAS, which showed a favorable result compared to interventional arm. The long-term preventive effect of other antiplatelet agents (clopidogrel, cilostazol, ticagrelor, aspirin plus dipyridamole) is not clearly defined and hence should be proven by future studies.

EXTRACRANIAL CAROTID ARTERY STENOSIS

Extracranial carotid artery stenosis is a major risk factor for ischemic stroke. Previous randomized clinical trials have compared carotid endarterectomy (CEA) with optimal medical therapy in patients with recent stroke or TIA.31-34) The stroke guideline recommends that CEA be used to reduce the risk of future stroke in patients with TIA or non-disabling ischemic stroke and ipsilateral severe (50–99%) carotid artery stenosis. Moreover, carotid artery stenting is considered an option for patients at high-risk of CEA complications.

The intensive medical therapies available for the prevention of stroke recurrence in patients with carotid artery stenosis include antiplatelet therapy, lipid-lowering therapy, and treatment of hypertension. The antiplatelet regimens of ongoing clinical trials in patients with carotid artery stenosis include aspirin 325 mg daily in the CREST-2 trial, and combined aspirin and dipyridamole or clopidogrel in the ECST-2 trial.35)36)

Dual antiplatelet therapy is not routinely recommended for the secondary prevention of ischemic stroke with symptomatic carotid artery stenosis, unless the symptoms are minor and within the acute period after symptom onset (described above). The CARESS trial demonstrated that combination therapy with clopidogrel and aspirin was more effective than using aspirin alone in reducing asymptomatic embolization in patients with recent (within 3 months) symptomatic carotid stenosis.37) Although this study used a surrogate marker of microembolic signal instead of clinical outcomes and short duration (7 days) of dual antiplatelet administration, it demonstrated the possible role of dual antiplatelet agent in symptomatic carotid artery stenosis.

LACUNAR INFARCTION

Small subcortical strokes, also known as lacunar infarction, comprise approximately onefourth of all cerebral infarctions. The Secondary Prevention of Small Subcortical Strokes (SPS3) study was a clinical trial that investigated the prevention of stroke recurrence by comparing aspirin plus placebo versus dual antiplatelet therapy with aspirin and clopidogrel.38) The addition of clopidogrel to aspirin did not significantly reduce the risk of recurrent stroke but increased the risk of bleeding and death significantly. In the SPS3 trial, the median time from the date of the qualifying stroke to randomization was 62 days; therefore, the result does not reflect the effect of dual antiplatelet medication in acute stage stroke prevention. Lacunar infarction that is detected within 24 hours of symptom onset and minor symptom (NIHSS ≤3) should be treated with dual antiplatelet as recommended by the guideline. The SPS3 trial subgroup analysis showed that in Caucasians receiving aspirin and clopidogrel, patients with cytochrome P450 2C19 (CYP2C19) intermediate or poor metabolizer status had higher probability of recurrent stroke than those with extensive or ultrarapid metabolizer status.39) However, this study is limited by the small proportion of Caucasian participants that showed significant results; thus, the results should be interpreted with caution, and a larger clinical trial is necessary to validate the conclusions.

SINGLE ANTIPLATELET AGENT AND ANTIPLATELET RESISTANCE

The American Heart Association stroke guideline recommends antiplatelet therapy in preference to oral anticoagulation to reduce the risk of recurrent ischemic stroke in patients with non-cardioembolic ischemic stroke or TIA.15) Aspirin 50–325 mg daily, clopidogrel 75 mg, or the combination of aspirin 25 mg and extended-release dipyridamole 200 mg twice daily is recommended for the secondary prevention of ischemic stroke, unless there are specific contraindications, such as minor ischemic stroke, high-risk TIA, or stroke due to large vessel occlusive disease.

The ESPRIT and ESPS2 trials showed that the use of aspirin-dipyridamole is more effective than aspirin alone for the prevention of vascular events.20)21) Although the CAPRIE trial was not focused strictly on the secondary prevention of ischemic stroke, it showed fewer composite vascular events among patients treated with clopidogrel than those treated with aspirin; however, there was no benefit in stroke reduction among the stroke subgroup.40) The PRoFESS trial found no significant difference between the use of aspirin-dipyridamole and clopidogrel in terms of secondary stroke prevention after non-cardioembolic stroke.19)

Clopidogrel is widely used as a single or dual combination antiplatelet for secondary prevention in patients with ischemic stroke. The CYP2C19 genotype differentially affects the liver metabolism of clopidogrel, which may influence the preventive effect. Studies on whether the stroke preventive effect differs by CYP2C19 genotype in ischemic stroke patients have shown controversial results. Previous studies demonstrated that reduced or loss of CYP2C19 function was associated with poorer outcome and increased risk of recurrent stroke in patients with ischemic stroke.41)42) In contrast, no significant association between CYP2C19 genotype and ischemic events was found in patients with ischemic stroke.43) In the SPS3 study, there were no significant differences in the occurrence of recurrent stroke by CYP2C19 metabolizer status in the whole study group.39) Moreover, a meta-analysis showed that carriers of CYP2C19 loss-of-function alleles (*2, *3, and *8) were at a 1.92-fold greater risk of stroke than non-carriers.44)

Several clinical trials are ongoing to verify the clinical implication of the CYP2C19 genotype on the preventive effect of clopidogrel in ischemic stroke.45)46)

CONCLUSION

Antiplatelet agents are used for the secondary prevention of cerebral infarction; however, they do not completely prevent the recurrence of cerebral infarction and may have the disadvantage of bleeding as a side effect. Dual antiplatelet therapy is recommended only for patients with acute mild cerebral infarction and cerebral infarction caused by severe arterial stenosis. However, the long-term effect of dual antiplatelet therapy and its use in other situations have not been completely established.

Further studies are needed on the long-term administration of dual antiplatelet agents in patients with cerebral infarction and cerebral artery stenosis or moderate to severe ischemic damage. The clinical implications of antiplatelet resistance, especially clopidogrel, in ischemic stroke prevention, is another important issue that requires further investigation.

Notes

Conflict of Interest

The author has no financial conflicts of interest.

References

1. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18:439–58.

2. Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Školoudík D, Steg PG, Touboul PJ, Uchiyama S, Vicaut É, Wong LKS, ; TIAregistry.org Investigators. One-year risk of stroke after transient ischemic attack or minor stroke. N Engl J Med 2016;374:1533–42.

3. Amarenco P, Lavallée PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, Anticoli S, Audebert H, Bornstein NM, Caplan LR, Correia M, Donnan GA, Ferro JM, Gongora-Rivera F, Heide W, Hennerici MG, Kelly PJ, Král M, Lin HF, Molina C, Park JM, Purroy F, Rothwell PM, Segura T, Školoudík D, Steg PG, Touboul PJ, Uchiyama S, Vicaut É, Wang Y, Wong LKS, ; TIAregistry.org Investigators. Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med 2018;378:2182–90.

4. Diener HC, Hankey GJ. Primary and secondary prevention of ischemic stroke and cerebral hemorrhage: JACC focus seminar. J Am Coll Cardiol 2020;75:1804–18.

5. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, Sidney S. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007;369:283–92.

6. Coull AJ, Lovett JK, Rothwell PM; Oxford Vascular Study. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004;328:326.

7. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in populationbased incidence studies. Neurology 2004;62:569–73.

8. Kleindorfer D, Panagos P, Pancioli A, Khoury J, Kissela B, Woo D, Schneider A, Alwell K, Jauch E, Miller R, Moomaw C, Shukla R, Broderick JP. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005;36:720–3.

9. Bowry AD, Brookhart MA, Choudhry NK. Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events. Am J Cardiol 2008;101:960–6.

10. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ; MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331–7.

11. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY, ; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N Engl J Med 2018;379:215–25.

12. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, Wang C, Li H, Meng X, Cui L, Jia J, Dong Q, Xu A, Zeng J, Li Y, Wang Z, Xia H, Johnston SC, ; CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11–9.

13. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, ; THALES Investigators. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med 2020;383:207–17.

14. Brown DL, Levine DA, Albright K, Kapral MK, Leung LY, Reeves MJ, Sico J, Strong B, Whiteley WN, ; American Heart Association Stroke Council. Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: a systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2021;52:e468–79.

15. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, Kamel H, Kernan WN, Kittner SJ, Leira EC, Lennon O, Meschia JF, Nguyen TN, Pollak PM, Santangeli P, Sharrief AZ, Smith SC Jr, Turan TN, Williams LS. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke 2021;52:e364–467.

16. Hao Q, Tampi M, O'Donnell M, Foroutan F, Siemieniuk RA, Guyatt G. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. BMJ 2018;363:k5108.

17. Ding L, Peng B. Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis. Eur J Neurol 2018;25:1276–84.

18. Patti G, Sticchi A, Bisignani A, Pelliccia F, Pasceri V, Speciale G, Penco M. Meta-regression to identify patients deriving the greatest benefit from dual antiplatelet therapy after stroke or transient ischemic attack without thrombolytic or thrombectomy treatment. Am J Cardiol 2019;124:627–35.

19. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, Bornstein N, Chan BP, Chen ST, Cunha L, Dahlöf B, De Keyser J, Donnan GA, Estol C, Gorelick P, Gu V, Hermansson K, Hilbrich L, Kaste M, Lu C, Machnig T, Pais P, Roberts R, Skvortsova V, Teal P, Toni D, Vandermaelen C, Voigt T, Weber M, Yoon BW, ; PRoFESS Study Group. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238–51.

20. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665–73.

21. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.

22. Yaghi S, Prabhakaran S, Khatri P, Liebeskind DS. Intracranial atherosclerotic disease. Stroke 2019;50:1286–93.

23. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: a large worldwide burden but a relatively neglected frontier. Stroke 2008;39:2396–9.

24. Kim JS, Bang OY. Medical treatment of intracranial atherosclerosis: an update. J Stroke 2017;19:261–70.

25. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Clof HJ, ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993–1003.

26. Zaidat OO, Fitzsimmons BF, Woodward BK, Wang Z, Killer-Oberpfalzer M, Wakhloo A, Gupta R, Kirshner H, Megerian JT, Lesko J, Pitzer P, Ramos J, Castonguay AC, Barnwell S, Smith WS, Gress DR, ; VISSIT Trial Investigators. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 2015;313:1240–8.

27. Sangha RS, Naidech AM, Corado C, Ansari SA, Prabhakaran S. Challenges in the medical management of symptomatic intracranial stenosis in an urban setting. Stroke 2017;48:2158–63.

28. Compter A, van der Worp HB, Schonewille WJ, Vos JA, Boiten J, Nederkoorn PJ, Uyttenboogaart M, Lo RT, Algra A, Kappelle LJ, ; VAST investigators. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. Lancet Neurol 2015;14:606–14.

29. Gao P, Zhao Z, Wang D, Wu J, Cai Y, Li T, Wu W, Shi H, He W, Zhu F, Jiao L, Ling F. China Angioplasty and Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a new, prospective, multicenter, randomized controlled trial in China. Interv Neuroradiol 2015;21:196–204.

30. Hurford R, Wolters FJ, Li L, Lau KK, Küker W, Rothwell PM, ; Oxford Vascular Study Phenotyped Cohort. Prevalence, predictors, and prognosis of symptomatic intracranial stenosis in patients with transient ischaemic attack or minor stroke: a population-based cohort study. Lancet Neurol 2020;19:413–21.

31. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, Warlow CP, Barnett HJ, ; Carotid Endarterectomy Trialists' Collaboration. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003;361:107–16.

32. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998;351:1379–87.

33. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, Haynes RB, Rankin RN, Clagett GP, Hachinski VC, Sackett DL, Thorpe KE, Meldrum HE, Spence JD. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1998;339:1415–25.

34. Meschia JF, Klaas JP, Brown RD Jr, Brott TG. Evaluation and management of atherosclerotic carotid stenosis. Mayo Clin Proc 2017;92:1144–57.

35. Howard VJ, Meschia JF, Lal BK, Turan TN, Roubin GS, Brown RD Jr, Voeks JH, Barrett KM, Demaerschalk BM, Huston J 3rd, Lazar RM, Moore WS, Wadley VG, Chaturvedi S, Moy CS, Chimowitz M, Howard G, Brott TG, ; CREST-2 study investigators. Carotid revascularization and medical management for asymptomatic carotid stenosis: protocol of the CREST-2 clinical trials. Int J Stroke 2017;12:770–8.

36. Stroke Research Group, ; UCL Institute of Neurology. ECST-2 protocol summary: version 3.10 [Internet]. London: Stroke Research Group, UCL Institute of Neurology; 2015. [cited 2021 Aug 31]. Available from: http://s489637516.websitehome.co.uk/ECST2/protocolsummary.

37. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233–40.

38. SPS3 Investigators, Benavente OR, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817–25.

39. McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J Am Heart Assoc 2015;4e001652.

40. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996;348:1329–39.

41. Lin YJ, Li JW, Zhang MJ, Qian L, Yang WJ, Zhang CL, Shao Y, Zhang Y, Huang YJ, Xu Y. The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment. CNS Neurosci Ther 2014;20:125–30.

42. Jia DM, Chen ZB, Zhang MJ, Yang WJ, Jin JL, Xia YQ, Zhang CL, Shao Y, Chen C, Xu Y. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. Stroke 2013;44:1717–9.

43. Qiu LN, Sun Y, Wang L, Han RF, Xia XS, Liu J, Li X. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel. Eur J Pharmacol 2015;747:29–35.

44. Pan Y, Chen W, Xu Y, Yi X, Han Y, Yang Q, Li X, Huang L, Johnston SC, Zhao X, Liu L, Zhang Q, Wang G, Wang Y, Wang Y. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Circulation 2017;135:21–33.

45. Wang Y, Johnston C, Bath PM, Meng X, Jing J, Xie X, Wang A, Pan Y, Xu A, Dong Q, Wang Y, Zhao X, Li Z, Li H, ; CHANCE-2 Investigators. Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial. Stroke Vasc Neurol 2021;6:280–5.

46. Song TJ, Kim J, Han SW, Kim YD, Lee JY, Ahn SH, Lee HS, Jung YH, Lee KY. Clopidogrel preventive effect based on cytochrome P450 2C19 genotype in ischaemic stroke: protocol for multicentre observational study. BMJ Open 2020;10e038031.

Article information Continued

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Trial	Population	Time window	Antiplatelet intervention	Primary outcome (efficacy & safety)	Key results
CHANCE12)	5,170 patients of minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD² score ≥4)	24 hours	Clopidogrel (300 mg load then 75 mg/day) plus aspirin 75 mg/day for 21 days then aspirin only vs. aspirin 75 mg/day	Recurrent stroke at 90 days	Reduced recurrent stroke in DAPT (HR, 0.68; p<0.001)
CHANCE12)		24 hours		Moderate to severe bleeding	No differences in moderate to severe bleeding
POINT11)	4,881 patients of minor ischemic stroke (NIHSS ≤3) or high-risk TIA (ABCD² score ≥4)	12 hours	Clopidogrel (600 mg load then 75 mg/day) plus aspirin 50–325 mg/ day vs. aspirin 50–325 mg/day for 90 days	Composite of major ischemic event at 90 days	Reduced major ischemic event in DAPT (HR, 0.75; p=0.02)
POINT11)		12 hours		Major hemorrhage	Increased major hemorrhage in DAPT (HR, 2.32; p=0.02)
THALES13)	11,016 patients of minor ischemic stroke (NIHSS ≤5) or high-risk TIA (ABCD² score ≥6 or symptomatic arterial stenosis)	24 hours	Ticagrelor (180 mg load then 90 mg twice daily) plus aspirin (load 300–325 mg then 75–100 mg/day) vs. aspirin (load 300–325 mg then 75–100 mg/day) for 30 days	Composite of stroke or death at 30 days	Reduced stroke or death in DAPT (HR, 0.83; p=0.02)
THALES13)		24 hours		Severe bleeding	Increased severe bleeding in DAPT (HR, 3.99; p=0.001)

Trial	Population	Intervention	Outcome	Follow-up duration	Antiplatelet medication for best medical management	Key results
SAMMPRIS25)	451 patients of TIA or nondisabling stroke with 70–99% stenosis of major intracranial artery	Stenting vs. best medical management	Stroke or death	Mean 11.9 months	Aspirin 325 mg per day for entire follow up and clopidogrel 75 mg per day for 90 days	Stenting resulted in more strokes and death
VISSIT26)	112 patients of hard TIA or stroke with 70–99% stenosis of major intracranial artery	Stenting vs. best medical management	Stroke or hard TIA	12 months	Aspirin 81–325 mg per day for entire follow up and clopidogrel 75 mg per day for 90 days	Stenting resulted in more strokes and hard TIA
VAST28)	115 patients of TIA or minor stroke with at least 50% stenosis of intra or extracranial vertebral artery	Stenting vs. best medical management	Vascular death, MI, stroke	Median 3 years	Not defined	Stenting did not lower the risk of stroke
VAST28)		Stenting vs. best medical management	Vascular death, MI, stroke	Median 3 years	Discretion of the treating neurologist	Stenting did not lower the risk of stroke
CASSISS29)	380 patients of TIA or stroke with 70–99% stenosis of major intracranial artery	Stenting vs. best medical management	Stroke or death	36 months	Aspirin 100 mg per day for entire follow up and clopidogrel 75 mg per day for 90 days	On going